Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/116572
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Roehnisch, Tim | - |
dc.contributor.author | Martos-Contreras, Mari Carmen | - |
dc.contributor.author | Manoochehri, Mehdi | - |
dc.contributor.author | Nogueira da Silva, Mauro | - |
dc.contributor.author | Bremm, Franziska | - |
dc.contributor.author | Dörrie, Jan | - |
dc.contributor.author | Christoph, Jan | - |
dc.contributor.author | Kunz, Meik | - |
dc.contributor.author | Wolfgang, Schönharting | - |
dc.date.accessioned | 2024-07-17T06:07:42Z | - |
dc.date.available | 2024-07-17T06:07:42Z | - |
dc.date.issued | 2024 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/118530 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/116572 | - |
dc.description.abstract | This report details a case of pancreatic cancer with liver metastasis that exhibited a positive immune response to personalized immunization therapy. Our study involved the identification of neoantigens and their corresponding immunogenic peptides using an in-house bioinformatic pipeline. This process included the identification of somatic mutations through DNA/RNA sequencing of solid tumor tissue and blood liquid biopsy. Computational prediction techniques were then employed to identify novel epitopes, followed by the design and manufacture of patient-specific immunization peptides. In combination with standard-of-care chemotherapy, the patient received a sequence of 5 biweekly prime injections followed by 2 boost injections 2 and 5 months later. The peptides were emulsified in Montanide and the injection-site was conditioned with nivolumab and imiquimod. The combined regimen of peptide immunization and chemotherapy resulted in a notable decline in CA19-9 tumor marker levels following both prime and boost applications. Subsequent MRI assessments revealed a reduction in the size of liver metastases several months post-immunization initiation. Importantly, the patient showed and improved overall survival and reported an improved quality of life without experiencing significant treatment-related adverse effects. This case underscores the potential benefits of personalized peptide-based immunization as an adjunctive therapy in the treatment of advanced pancreatic cancer, showcasing promising outcomes in tumor marker reduction, tumor shrinkage, and enhanced patient well-being. | eng |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject.ddc | 610 | - |
dc.title | Individualized neoantigen peptide immunization of a metastatic pancreatic cancer patient: a case report of combined tumor and liquid biopsy | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Frontiers in immunology | - |
local.bibliographicCitation.volume | 15 | - |
local.bibliographicCitation.pagestart | 1 | - |
local.bibliographicCitation.pageend | 5 | - |
local.bibliographicCitation.publishername | Frontiers Media | - |
local.bibliographicCitation.publisherplace | Lausanne | - |
local.bibliographicCitation.doi | 10.3389/fimmu.2024.1414737 | - |
local.openaccess | true | - |
dc.identifier.ppn | 1895010993 | - |
cbs.publication.displayform | 2024 | - |
local.bibliographicCitation.year | 2024 | - |
cbs.sru.importDate | 2024-07-17T06:07:19Z | - |
local.bibliographicCitation | Enthalten in Frontiers in immunology - Lausanne : Frontiers Media, 2010 | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-15-1414737.pdf | 1.98 MB | Adobe PDF | ![]() View/Open |